WOONSOCKET, R.I., June 14 /PRNewswire-FirstCall/ — MultiCell
Technologies, Inc. (OTC Bulletin Board: MCET) has retained Clinical
Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned
Phase IIb clinical trial in the United
Kingdom for MCT-125, the Company’s lead drug candidate for
treatment of primary multiple sclerosis-related fatigue (PMSF).
In an earlier Phase IIa study, MCT-125 was tested on 138
patients suffering from PMSF. MCT-125 was shown to be
effective within 4 weeks of administration, was active across all
multiple sclerosis (MS) disease severity assessment scales, and on
patients regardless of MS disease sub-type (primary progressive,
secondary progressive and relapsing-remitting).
MCT-125 is a fixed dose, orally delivered, combination
therapeutic acting on noradrenergic neurons and tyrosine
hydroxylase to block the reuptake of noradrenaline with little or
no direct action on serotoninergic neurons. The synthesis of
noradrenaline in noradrenergic neurons is tightly regulated by
tyrosine hydroxylase acting as the key rate-limiting step.
MCT-125 is thought to lead to the greater availability of
noradrenaline in the central nervous system resulting in a decrease
in fatigue levels.
Multiple sclerosis is an autoimmune disease in which immune
cells attack and destroy the myelin sheath insulating neurons in
the brain and spinal cord. Approximately 350,000 individuals
have been diagnosed with MS in the United
States, and m
‘/>”/>
SOURCE
